Trade Sutro Biopharma, Inc. - STRO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Sutro Biopharma Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 3.33 |
| Open* | 3.26 |
| 1-Year Change* | -38.61% |
| Day's Range* | 3.26 - 3.35 |
| 52 wk Range | 3.99-8.72 |
| Average Volume (10 days) | 372.48K |
| Average Volume (3 months) | 8.77M |
| Market Cap | 274.79M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 60.53M |
| Revenue | 56.87M |
| EPS | -2.47 |
| Dividend (Yield %) | N/A |
| Beta | 0.86 |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 27, 2023 | 3.33 | 0.19 | 6.05% | 3.14 | 3.40 | 3.14 |
| Sep 26, 2023 | 3.27 | 0.06 | 1.87% | 3.21 | 3.41 | 3.21 |
| Sep 25, 2023 | 3.31 | 0.04 | 1.22% | 3.27 | 3.33 | 3.16 |
| Sep 22, 2023 | 3.27 | -0.06 | -1.80% | 3.33 | 3.37 | 3.22 |
| Sep 21, 2023 | 3.36 | -0.09 | -2.61% | 3.45 | 3.45 | 3.34 |
| Sep 20, 2023 | 3.53 | -0.07 | -1.94% | 3.60 | 3.69 | 3.42 |
| Sep 19, 2023 | 3.71 | 0.07 | 1.92% | 3.64 | 3.80 | 3.64 |
| Sep 18, 2023 | 3.75 | -0.09 | -2.34% | 3.84 | 3.84 | 3.65 |
| Sep 15, 2023 | 3.88 | -0.20 | -4.90% | 4.08 | 4.17 | 3.82 |
| Sep 14, 2023 | 4.19 | -0.31 | -6.89% | 4.50 | 4.62 | 4.16 |
| Sep 13, 2023 | 4.61 | 0.18 | 4.06% | 4.43 | 4.63 | 4.43 |
| Sep 12, 2023 | 4.52 | 0.01 | 0.22% | 4.51 | 4.65 | 4.42 |
| Sep 11, 2023 | 4.58 | 0.27 | 6.26% | 4.31 | 4.63 | 4.26 |
| Sep 8, 2023 | 4.49 | -0.01 | -0.22% | 4.50 | 4.55 | 4.43 |
| Sep 7, 2023 | 4.52 | 0.16 | 3.67% | 4.36 | 4.56 | 4.33 |
| Sep 6, 2023 | 4.49 | 0.33 | 7.93% | 4.16 | 4.50 | 4.16 |
| Sep 5, 2023 | 4.38 | 0.09 | 2.10% | 4.29 | 4.53 | 4.23 |
| Sep 1, 2023 | 4.48 | -0.14 | -3.03% | 4.62 | 4.80 | 4.33 |
| Aug 31, 2023 | 4.72 | 0.11 | 2.39% | 4.61 | 4.93 | 4.61 |
| Aug 30, 2023 | 4.82 | 0.15 | 3.21% | 4.67 | 4.84 | 4.62 |
Sutro Biopharma, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Sutro Biopharma Inc Earnings Release Q3 2023 Sutro Biopharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 67.772 | 61.88 | 42.722 | 42.736 | 38.419 |
| Revenue | 67.772 | 61.88 | 42.722 | 42.736 | 38.419 |
| Total Operating Expense | 196.715 | 160.404 | 113.779 | 98.204 | 75.642 |
| Selling/General/Admin. Expenses, Total | 59.544 | 56.004 | 36.818 | 32.592 | 21.38 |
| Research & Development | 137.171 | 104.4 | 76.961 | 65.612 | 54.262 |
| Operating Income | -128.943 | -98.524 | -71.057 | -55.468 | -37.223 |
| Interest Income (Expense), Net Non-Operating | 12.239 | -7.014 | 38.929 | -0.276 | -0.007 |
| Other, Net | 1.913 | ||||
| Net Income Before Taxes | -116.704 | -105.538 | -32.128 | -55.744 | -35.317 |
| Net Income After Taxes | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Net Income Before Extra. Items | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Net Income | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Income Available to Common Excl. Extra. Items | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Income Available to Common Incl. Extra. Items | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Diluted Net Income | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Diluted Weighted Average Shares | 50.7392 | 46.1191 | 32.5735 | 22.9586 | 22.8482 |
| Diluted EPS Excluding Extraordinary Items | -2.34935 | -2.28838 | -0.98632 | -2.42803 | -1.54572 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Diluted Normalized EPS | -2.34935 | -2.28838 | -0.98632 | -2.42803 | -1.54572 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 10.412 | 12.674 | 8.632 | 25.147 | 28.096 |
| Revenue | 10.412 | 12.674 | 8.632 | 25.147 | 28.096 |
| Total Operating Expense | 56.591 | 54.911 | 57.854 | 46.357 | 47.475 |
| Selling/General/Admin. Expenses, Total | 14.999 | 15.512 | 14.719 | 14.643 | 15.143 |
| Research & Development | 41.592 | 39.399 | 43.135 | 31.714 | 32.332 |
| Operating Income | -46.179 | -42.237 | -49.222 | -21.21 | -19.379 |
| Interest Income (Expense), Net Non-Operating | 8.248 | -7.418 | 14.628 | 1.722 | -4.133 |
| Net Income Before Taxes | -38.373 | -49.655 | -34.594 | -19.488 | -23.512 |
| Net Income After Taxes | -38.524 | -50.05 | -34.594 | -19.488 | -26.012 |
| Net Income Before Extra. Items | -38.524 | -50.05 | -34.594 | -19.488 | -26.012 |
| Net Income | -38.524 | -50.05 | -34.594 | -19.488 | -26.012 |
| Income Available to Common Excl. Extra. Items | -38.524 | -50.05 | -34.594 | -19.488 | -26.012 |
| Income Available to Common Incl. Extra. Items | -38.524 | -50.05 | -34.594 | -19.488 | -26.012 |
| Diluted Net Income | -38.524 | -50.05 | -34.594 | -19.488 | -26.012 |
| Diluted Weighted Average Shares | 60.3395 | 58.7234 | 57.09 | 52.3457 | 46.9572 |
| Diluted EPS Excluding Extraordinary Items | -0.63845 | -0.8523 | -0.60596 | -0.37229 | -0.55395 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.63845 | -0.8523 | -0.60596 | -0.37229 | -0.55395 |
| Other, Net | -0.442 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 353.153 | 218.515 | 378.182 | 128.568 | 209.946 |
| Cash and Short Term Investments | 334.364 | 197.938 | 368.137 | 117.864 | 204.492 |
| Cash & Equivalents | 47.254 | 30.414 | 206.152 | 4.96 | 125.298 |
| Short Term Investments | 287.11 | 167.524 | 161.985 | 112.904 | 79.194 |
| Total Receivables, Net | 7.122 | 12.454 | 5.559 | 6.298 | 2.489 |
| Accounts Receivable - Trade, Net | 7.122 | 12.454 | 5.559 | 6.298 | 2.489 |
| Prepaid Expenses | 11.667 | 8.123 | 4.486 | 4.406 | 2.965 |
| Total Assets | 406.944 | 341.408 | 394.111 | 156.37 | 223.139 |
| Property/Plant/Equipment, Total - Net | 51.064 | 51.591 | 12.935 | 9.633 | 10.934 |
| Property/Plant/Equipment, Total - Gross | 88.969 | 85.017 | 49.762 | 43.481 | 40.23 |
| Accumulated Depreciation, Total | -37.905 | -33.426 | -36.827 | -33.848 | -29.296 |
| Other Long Term Assets, Total | 2.727 | 2.527 | 2.994 | 2.56 | 2.259 |
| Total Current Liabilities | 66.547 | 41.736 | 29.597 | 32.967 | 36.423 |
| Accounts Payable | 4.797 | 11.327 | 5.544 | 5.584 | 3.061 |
| Accrued Expenses | 32.491 | 12.454 | 8.823 | 6.017 | 6.217 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 12.5 | 9.375 | 0 | 1 | 4.724 |
| Other Current Liabilities, Total | 16.759 | 8.58 | 15.23 | 20.366 | 22.421 |
| Total Liabilities | 189.896 | 88.844 | 62.063 | 58.581 | 91.6 |
| Total Long Term Debt | 3.771 | 15.738 | 24.545 | 8.876 | 10 |
| Long Term Debt | 3.771 | 15.738 | 24.545 | 8.876 | 10 |
| Other Liabilities, Total | 119.578 | 31.37 | 7.921 | 16.738 | 45.177 |
| Total Equity | 217.048 | 252.564 | 332.048 | 97.789 | 131.539 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Common Stock | 0.058 | 0.046 | 0.046 | 0.023 | 0.023 |
| Additional Paid-In Capital | 670.223 | 586.243 | 559.746 | 293.346 | 281.891 |
| Retained Earnings (Accumulated Deficit) | -452.615 | -333.411 | -227.873 | -195.745 | -150.328 |
| Other Equity, Total | -0.618 | -0.314 | 0.129 | 0.165 | -0.047 |
| Total Liabilities & Shareholders’ Equity | 406.944 | 341.408 | 394.111 | 156.37 | 223.139 |
| Total Common Shares Outstanding | 57.4995 | 46.3812 | 45.7521 | 23.099 | 22.8482 |
| Long Term Investments | 0 | 68.775 | 0 | 15.609 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 304.063 | 353.153 | 346.553 | 331.511 | 228.742 |
| Cash and Short Term Investments | 276.494 | 334.364 | 324.248 | 225.636 | 209.145 |
| Cash & Equivalents | 62.472 | 47.254 | 96.779 | 79.115 | 28.901 |
| Short Term Investments | 214.022 | 287.11 | 227.469 | 146.521 | 180.244 |
| Total Receivables, Net | 9.873 | 7.122 | 11.241 | 97.671 | 11.686 |
| Accounts Receivable - Trade, Net | 9.873 | 7.122 | 11.241 | 97.671 | 11.686 |
| Prepaid Expenses | 17.696 | 11.667 | 11.064 | 8.204 | 7.911 |
| Total Assets | 358.016 | 406.944 | 400.7 | 385.62 | 303.675 |
| Property/Plant/Equipment, Total - Net | 49.831 | 51.064 | 51.354 | 51.316 | 51.657 |
| Long Term Investments | 0 | 0 | 0 | 20.699 | |
| Other Long Term Assets, Total | 4.122 | 2.727 | 2.793 | 2.793 | 2.577 |
| Total Current Liabilities | 59.486 | 66.547 | 58.288 | 44.572 | 38.76 |
| Accounts Payable | 5.058 | 4.797 | 12.443 | 12.567 | 10.705 |
| Accrued Expenses | 24 | 32.491 | 13.011 | 8.868 | 6.486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 17.186 | 16.759 | 20.334 | 10.637 | 9.069 |
| Total Liabilities | 172.603 | 189.896 | 170.974 | 176.562 | 83.303 |
| Total Long Term Debt | 0 | 3.771 | 6.783 | 9.779 | 12.762 |
| Long Term Debt | 0 | 3.771 | 6.783 | 9.779 | 12.762 |
| Other Liabilities, Total | 113.117 | 119.578 | 105.903 | 122.211 | 31.781 |
| Total Equity | 185.413 | 217.048 | 229.726 | 209.058 | 220.372 |
| Common Stock | 0.06 | 0.058 | 0.055 | 0.049 | 0.047 |
| Additional Paid-In Capital | 688.125 | 670.223 | 649.028 | 608.898 | 593.998 |
| Retained Earnings (Accumulated Deficit) | -502.665 | -452.615 | -418.021 | -398.533 | -372.521 |
| Total Liabilities & Shareholders’ Equity | 358.016 | 406.944 | 400.7 | 385.62 | 303.675 |
| Total Common Shares Outstanding | 60.1618 | 57.4995 | 54.6314 | 48.6742 | 46.3271 |
| Current Port. of LT Debt/Capital Leases | 13.242 | 12.5 | 12.5 | 12.5 | 12.5 |
| Other Equity, Total | -0.107 | -0.618 | -1.336 | -1.356 | -1.152 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Cash From Operating Activities | 3.549 | -81.679 | -67.802 | -65.023 | 12.683 |
| Cash From Operating Activities | 5.69 | 4.844 | 4.297 | 4.777 | 4.539 |
| Non-Cash Items | 12.658 | 36.635 | -28.485 | 9.208 | 0.855 |
| Cash Interest Paid | 1.869 | 2.046 | 1.675 | 1.049 | 1.275 |
| Changes in Working Capital | 104.405 | -17.62 | -11.486 | -23.264 | 42.606 |
| Cash From Investing Activities | -35.022 | -97.315 | 0.604 | -51.131 | -80.19 |
| Capital Expenditures | -7.858 | -15.323 | -7.129 | -3.481 | -1.557 |
| Other Investing Cash Flow Items, Total | -27.164 | -81.992 | 7.733 | -47.65 | -78.633 |
| Cash From Financing Activities | 48.313 | 3.256 | 269.247 | -4.184 | 170.785 |
| Financing Cash Flow Items | -0.463 | 0.778 | -0.314 | 0.636 | 1.208 |
| Issuance (Retirement) of Stock, Net | 58.151 | 2.478 | 254.561 | 0.18 | 169.577 |
| Net Change in Cash | 16.84 | -175.738 | 202.049 | -120.338 | 103.278 |
| Issuance (Retirement) of Debt, Net | -9.375 | 0 | 15 | -5 | |
| Cash Taxes Paid | 0 | 0.103 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -50.05 | -119.204 | -84.61 | -65.122 | -39.11 |
| Cash From Operating Activities | -60.991 | 3.549 | 27.413 | -38.441 | -35.255 |
| Cash From Operating Activities | 1.615 | 5.69 | 4.162 | 2.724 | 1.327 |
| Non-Cash Items | 11.855 | 12.658 | 23.021 | 19.094 | 7.751 |
| Cash Interest Paid | 0.00039 | 1.869 | 1.442 | 0.998 | 0.504 |
| Changes in Working Capital | -24.411 | 104.405 | 84.84 | 4.863 | -5.223 |
| Cash From Investing Activities | 67.451 | -35.022 | 2.86 | 80.897 | 32.982 |
| Capital Expenditures | -0.942 | -7.858 | -4.491 | -3.753 | -1.553 |
| Other Investing Cash Flow Items, Total | 68.393 | -27.164 | 7.351 | 84.65 | 34.535 |
| Cash From Financing Activities | 8.758 | 48.313 | 36.092 | 6.245 | 0.76 |
| Financing Cash Flow Items | -0.451 | -0.463 | -0.463 | -0.413 | -0.426 |
| Issuance (Retirement) of Stock, Net | 12.334 | 58.151 | 42.805 | 9.783 | 1.186 |
| Issuance (Retirement) of Debt, Net | -3.125 | -9.375 | -6.25 | -3.125 | 0 |
| Net Change in Cash | 15.218 | 16.84 | 66.365 | 48.701 | -1.513 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | Hedge Fund | 9.7208 | 5883693 | 194607 | 2023-06-30 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.7021 | 4661830 | 734685 | 2023-06-30 | LOW |
| Rubric Capital Management LP | Hedge Fund | 6.6891 | 4048744 | -311743 | 2023-06-30 | MED |
| BVF Partners L.P. | Hedge Fund | 5.5313 | 3347946 | 0 | 2023-06-30 | LOW |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 4.6992 | 2844281 | 28704 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.6754 | 2829908 | 52946 | 2023-06-30 | LOW |
| Holocene Advisors, LP | Hedge Fund | 3.5238 | 2132873 | 0 | 2023-06-30 | HIGH |
| Verition Fund Management LLC | Hedge Fund | 3.2162 | 1946660 | 800874 | 2023-06-30 | HIGH |
| Baillie Gifford & Co. | Investment Advisor | 3.0857 | 1867654 | 0 | 2023-06-30 | LOW |
| Samsara BioCapital, LLC | Venture Capital | 2.7683 | 1675579 | 0 | 2023-06-30 | LOW |
| Candriam Belgium S.A. | Investment Advisor/Hedge Fund | 2.6901 | 1628234 | -232541 | 2023-06-30 | MED |
| Candriam Luxembourg S.A. | Investment Advisor | 2.69 | 1628181 | 0 | 2023-06-30 | MED |
| Millennium Management LLC | Hedge Fund | 2.4842 | 1503594 | 611978 | 2023-06-30 | HIGH |
| Kynam Capital Management LP | Hedge Fund | 2.4782 | 1500000 | 598164 | 2023-06-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.0021 | 1211788 | 38589 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.919 | 1161532 | 105218 | 2023-06-30 | LOW |
| Parkman Healthcare Partners LLC | Hedge Fund | 1.8898 | 1143861 | 43823 | 2023-06-30 | HIGH |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.8077 | 1094121 | -1828591 | 2023-06-30 | LOW |
| Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.6249 | 983488 | -100529 | 2023-06-30 | LOW |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.3336 | 807207 | 4056 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Sutro Biopharma, Inc. Company profile
About Sutro Biopharma Inc
Sutro Biopharma, Inc. is a clinical stage drug discovery, development, and manufacturing company. It is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. It is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Sutro Biopharma Inc revenues increased 45% to $61.9M. Net loss increased from $32.1M to $105.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Unrealized (loss) gain on equity securit decrease from $41.5M (income) to $4.5M (expense), Research and development increase of 31% to $97.3M (expense).
| Industry: | Bio Therapeutic Drugs |
111 Oyster Point Blvd.
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com